Japanese company profile · 4576

D.Western Therapeutics Institute, Inc.

English company name recorded in Japan's EDINET filer data.

Original Japanese company name: 株式会社デ・ウエスタン・セラピテクス研究所

Name follows the English name recorded in EDINET filer data. English company name source

FY2025 · fiscal year ended December 2025Latest filing date: 2026-03-23

What does this company do?

What does this company do?

In its FY2025 public filing, D.Western Therapeutics Institute, Inc. reports Drug Discovery. The page shows business-level revenue and profit where the source disclosures support comparison.

D.Western Therapeutics Institute, Inc.'s largest reported business by revenue in FY2025 was Drug Discovery.

FY2025 · fiscal year ended December 2025 · View original filing ↗ The source document may be in Japanese.

Reported company-wide figures

Company revenue
¥387.62M ↗
FY2025 · fiscal year ended December 2025
Operating profit
−¥619.87M ↗
FY2025 · fiscal year ended December 2025
Comparable margin
-159.9% ↗
FY2025 · fiscal year ended December 2025

JGAAP · Consolidated company-wide

Company profile

Company profile

Identity

Securities code
4576
EDINET code
E22024
Corporate number
5180001055013
Listing status
Listed
Industry (EDINET filer classification)
Pharmaceuticals

Location and fiscal year

Headquarters
名古屋市中区 · As filed in Japanese
Fiscal year end
12month
Latest fiscal year
FY2025
Accounting standard
JGAAP
P16 data snapshot
2026-11-07

Company size

Employees (consolidated)
19 people (FY2025)
Employees (non-consolidated)
19 people (FY2025)
Capital stock
JPY 697.3 million (FY2025)

Official information

Public information is organized and presented by P16. EDINET filer list (2026-11-07) Opens in a new tab · EDINET PDL 1.0 terms Opens in a new tab

Business structure

How does it make money?

FY2025 · fiscal year ended December 2025 · Business Sales Operating profit
BusinessSalesShare of company salesOperating profitMargin
Drug Discovery¥387.62M ↗—−¥619.87M ↗-159.9%

All values are in Japanese yen (JPY). No currency conversion is applied. FY2025 · fiscal year ended December 2025. Revenue and profit are shown only where the filing and data support a comparison. “—” means a comparable amount was not disclosed. We compare sales to outside customers for each business and the company as a whole, using the same filing, fiscal year and scope. Reported business sales may include sales between businesses. We leave the share blank when the figures cannot be matched.

Company revenue

Company-wide trend

Company revenue

JGAAP · Consolidated
  1. FY202187.9¥414.42M
  2. FY202295.0¥448.1M
  3. FY202390.8¥428.36M
  4. FY2024100.0¥471.58M
  5. FY202582.2¥387.62M

Company operating profit

JGAAP · Consolidated
  1. FY202114.2−¥171.65M
  2. FY202225.3−¥305.91M
  3. FY202366.0−¥798.56M
  4. FY2024100.0−¥1.21B
  5. FY202551.2−¥619.87M

Only reported years are shown. Missing years are left blank; accounting standards and scopes are kept in separate series.

Reported Sales by business over time

Reported Sales by business over time

Fiscal yearFY2021FY2022FY2023FY2024FY2025
Drug Discovery¥414.42M¥448.1M¥428.36M¥471.58M¥387.62M

All amounts are in Japanese yen (JPY). Each figure links to the original Japanese filing. Blank cells indicate no comparable figure was disclosed. Business figures may not add up to consolidated figures.

What is growing?

What is growing?

Business revenue growth

This describes a reported period; it is not a forecast.

What has changed?

What has changed?

A five-year business-mix comparison is not shown because the available filings do not provide five comparable years on the same basis.

Source

Company profile

These scores summarize company characteristics using public filings. Comparison groups vary by measure. Higher is not always better.

  • Growth11
    Position among all companies with available values in the fixed reference data.FY2021→FY2025
  • Profitability0
    Position among all companies with available values in the fixed reference data.FY2025
  • Business concentration—
    No comparable data
  • Business change—
    No comparable data
  • Cash generation—
    No comparable data
  • Growth persistence19
    Peer-position scoreFY2021→FY2022, FY2022→FY2023, FY2023→FY2024, FY2024→FY2025

Next

Ask about this company

Source

Public filing

FY2025 · fiscal year ended December 2025

The source document may be in Japanese.

Filing ID: S100XS4G

View original filing ↗

根拠となる資料